Business
Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs and Co-Founders of
About this update from Amylyx Pharmaceuticals, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAmylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs and Co-Founders of Amylyx, will present at the 11th Annual SVB Leerink Global Healthcare Conference. The conference is being conducted in a virtual format, and the presentation will take place on Thursday, February 17, 2022 at 4:20pm ET.\n\nA live webcast of the presentation can be accessed under “Events” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the event.\n\nAbout Amylyx Pharmaceuticals\nAmylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit www.investors.amylyx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220210005251/en/\n\nMedia\nBecky Gohsler\nFinn Partners\n(646) 307-6307\[email protected]\n\nInvestors\nLindsey Allen\nAmylyx Pharmaceuticals, Inc.\n(857) 320-6244\[email protected]\n\nSource: Amylyx Pharmaceuticals, Inc.","length":3876,"tagName":"div"}]